Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
Friday, November 22, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Precision BioSciences has announced promising preclinical data for PBGENE-HBV, which indicates a strong safety profile and the potential to provide a functional cure for chronic hepatitis B. This data supports the progression into a first-in-human clinical trial, named ELIMINATE-B, which will evaluate the safety and efficacy of the treatment.
Price reaction · baseline $6.5 (2024-11-21 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+11.7%
day 1
+11.4%
day 3
+9.4%
Market Sentiment Analysis
POSITIVE FACTORS
Preclinical data supports safety profile of PBGENE-HBV.
Potential to deliver a functional cure for chronic hepatitis B.
Advancement into first-in-human clinical study is planned.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study – – Phase 1 dose escalation and expansion trial, ELIMINATE-B, designed to assess safety and efficacy measured by
Frequently Asked Questions
What is PBGENE-HBV?
PBGENE-HBV is a treatment developed by Precision BioSciences aimed at chronic hepatitis B.
What does the preclinical data indicate?
The preclinical data suggests a strong safety profile and potential for a functional cure.
What is the ELIMINATE-B trial?
ELIMINATE-B is a Phase 1 trial designed to assess the safety and efficacy of PBGENE-HBV.
What stage is PBGENE-HBV currently in?
PBGENE-HBV is advancing into a first-in-human clinical study following preclinical success.